Dr. Eric J. Lawitz, MD

Dr. Lawitz practices at Texas Liver Institute in San Antonio, Texas.

Dr. Lawitz's NPI, 1578661716, was assigned on September 20, 2006. Dr. Lawitz graduated from Rush Medical College in 1993. Dr. Lawitz holds Texas license L6486.

Dr. Lawitz's primary practice is Texas Liver Institute, at 607 Camden St Ste 108 Suite 108, San Antonio, TX 78215. The practice phone is (210) 253-3426.

Dr. Lawitz's primary practice is Texas Liver Institute in San Antonio, Texas. Dr. Lawitz is also affiliated with University Hospital. The medical group on file is Texas Liver Institute. Dmand AI also links Dr. Lawitz to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lawitz practices, 6 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Lawitz's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Lawitz is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Lawitz's licenses on file in 2 states: Texas and Wisconsin.

Dmand AI lists cirrhosis of the liver and fatty liver among the conditions Dr. Lawitz treats.

CMS data shows 890 Medicare services from Dr. Lawitz across 10 procedure codes in 2024, for 473 Medicare patients. Medicare paid $48,803 for them. Every service was in an office.

CMS counts 473 Medicare patients who saw Dr. Lawitz in 2024. The largest group is 65 to 74, with 283 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lawitz's median patient age at 64, with 63% women.

In 2024, Dr. Lawitz wrote 537 Medicare Part D claims for 219 patients. 92% of them were for generic drugs. CMS names the drug for 466 of them, across 11 drugs with 11 or more claims each, at $56,347 in total drug cost. In 2023, CMS named 299 claims across 9 drugs.

Dr. Lawitz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 210 papers to Dr. Lawitz, published from 2004 to 2025. 2019 was the busiest year, with 17. The most frequent topics are Antiviral Agents, Hepatitis C, Chronic and Hepacivirus. Dr. Lawitz has published most often in J Hepatol. Dr. Lawitz's most frequent co-authors are Nezam H. Afdhal, MD, Thomas Crawford Marbury, MD and Reem H. Ghalib, MD.

Dmand AI links Dr. Lawitz to 17 clinical trials, 7 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Hepatitis C, Non-alcoholic Fatty Liver Disease and Fatty Liver. Bristol-Myers Squibb sponsors the most, 3. Open Payments lists research payments to Dr. Lawitz that name 2 trials.

CMS Open Payments shows 1,504 general payments to Dr. Lawitz from 32 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 49% of the total. Gilead Sciences, Inc. paid the most, $441,227. It also lists 72 research payments totaling $49,161 from 2017 to 2025, naming 2 clinical trials.

Dmand AI lists 4 awards for Dr. Lawitz, most recently FAASLD in 2016.

Dr. Lawitz graduated from Rush Medical College in 1993. Dr. Lawitz is a member of Academy of Physicians in Clinical Research, American Association for the Study of Liver Disease, AGA and European Association for the Study of the Liver.

Dr. Lawitz is in network with 23 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.